REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, based in Rockville, Maryland, has reported positive interim data from an ongoing Phase II “ALTITUDE” trial of… Read More »Regenxbio Inc.’s gene therapy treatment (RGX-314) for diabetic retinopathy (DR) reports positive interim data from Phase II.
A research team based at the Institute of Genetic Epidemiology, Medical University of Innsbruck, Austria, have shown that the relative telomere length (RTL) is associated… Read More »Relative telomere length (RTL) appears to be associated with age-related macular degeneration in women but not in men.
Researchers based at the Buck Institute for Research on Aging, in San Francisco, California, have reported results on the impact of dietary restriction, circadian rhythms… Read More »Research on dietary restriction and the molecular circadian rhythm aims to assess eye health and lifespan
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the June 16th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »June 16th, 2022 “EURETINA-Brief”© Issue No. 256
Teva Pharmaceitical (NYSE and TASE: TEVA) has announced that the UK Medicines & Healthcare Regulatory Agency (MHRA) is to grant a licence for “Ongavia”, a… Read More »Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA), has announced the licencing, the UK MHRA, of a biosimilar (“Ongavia”) to Lucentis (ranibizumab).
A research team based at the Faculty of Biology, Medicine and Health, University of Manchester, and the Manchester Royal Eye Hospital, NHS Foundation Trust, has… Read More »Early signs of age-related macular degeneration (AMD) may assist to treat patients before symptoms arise thereby interrupt the pathogenesis.
Researchers based at the John A. Moran Eye Centre, University of Utah, Salt Lake City, USA, have reported a significant study on the viability of… Read More »Light signalling in the post-mortem mouse and human retina may show significant implications on ophthalmic conditions and brain sciences.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 27th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »May 27th, 2022 “EURETINA-Brief”© Issue No. 255
MeiraGTx (Nasdaq: MGTX) has announced that additional clinical data from the Phase 1/2 trial of botaretigene sparoparvovec for the treatment of X-linked Retinitis Pigmentosa (XLRP)… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced preliminary efficacy data from a gene therapy for XLRP patients
A research team based at the National Eye Institute, National Institutes of Health, Bethesda, Maryland, has published long-term visual outcomes for patients participating with an… Read More »A real-world study on an AI-enabled tele-monitoring project shows significant impact on long-term outcomes.